Sandia National Laboratories, Albuquerque, New Mexico 87106, United States.
Center for Bioengineering, University of California Santa Barbara, Santa Barbara, California 93106, United States.
ACS Sens. 2022 Oct 28;7(10):2823-2832. doi: 10.1021/acssensors.2c01428. Epub 2022 Oct 7.
The continuous, real-time measurement of specific molecules in the body would greatly improve our ability to understand, diagnose, and treat disease. The vast majority of continuous molecular sensing technologies, however, either (1) rely on the chemical or enzymatic reactivity of their targets, sharply limiting their scope, or (2) have never been shown (and likely will never be shown) to operate in the complex environments found . Against this background, here we review electrochemical aptamer-based (EAB) sensors, an electrochemical approach to real-time molecular monitoring that has now seen 15 years of academic development. The strengths of the EAB platform are significant: to date it is the only molecular measurement technology that (1) functions independently of the chemical reactivity of its targets, and is thus general, and (2) supports measurements. Specifically, using EAB sensors we, and others, have already reported the real-time, seconds-resolved measurements of multiple, unrelated drugs and metabolites in the veins and tissues of live animals. Against these strengths, we detail the platform's remaining weaknesses, which include still limited measurement duration (hours, rather than the more desirable days) and the difficulty in obtaining sufficiently high performance aptamers against new targets, before then detailing promising approaches overcoming these hurdles. Finally, we close by exploring the opportunities we believe this potentially revolutionary technology (as well as a few, possibly competing, technologies) will create for both researchers and clinicians.
在体内对特定分子进行连续实时测量将极大地提高我们理解、诊断和治疗疾病的能力。然而,绝大多数连续分子传感技术要么(1)依赖于其靶标的化学或酶反应性,从而大大限制了其应用范围,要么(2)从未(可能永远不会)证明在复杂环境中起作用。在此背景下,我们在这里回顾了基于电化学适体的(EAB)传感器,这是一种实时分子监测的电化学方法,目前已经有 15 年的学术发展。EAB 平台具有显著的优势:迄今为止,它是唯一一种(1)不依赖于其靶标的化学反应性的分子测量技术,因此具有通用性,并且(2)支持实时测量的技术。具体来说,我们和其他人已经使用 EAB 传感器报告了实时、秒分辨率的多个相关药物和代谢物在活体动物静脉和组织中的测量结果。针对这些优势,我们详细说明了该平台仍然存在的弱点,包括测量持续时间仍然有限(小时,而不是更理想的几天),以及获得针对新靶标具有足够高性能适体的困难,然后详细介绍了克服这些障碍的有前景的方法。最后,我们通过探索我们认为这项潜在革命性技术(以及一些可能的竞争技术)将为研究人员和临床医生带来的机会来结束本文。